Abstract

Representative B-butyl- and B-methyl-1,3,2-oxazaborolidines derived from ephedrine and norephedrine were prepared in good yield and excellent purity by one pot treatment of B-H oxazaborolidines with the corresponding organolithium reagent, and subsequent hydrolysis of the cyclic borohydride intermediate with anhydrous ammonium chloride.
Chiral 1,3,2-oxazaborolidines have been well studied and regarded as important catalysts for the enantioselective reduction of prochiral ketones, imines and oximes, 1,2,3 and in other stereoselective transformations.4 The development of oxazaborolidines has been limited mainly by the availability of suitable chiral amino alcohols. Norephedrine and ephedrine are commercially available and relatively inexpensive in their two enantiomeric forms. Consequently, their derived oxazaborolidines, and particularly the B-alkyl substituted systems, have been widely investigated and reported as highly efficient chiral templates for the borane reduction of prochiral ketones5 and C=N double bonds,6 in catalytic hydroboration,7 as well as in addition of diethylzinc to aldehydes.8
B-H oxazaborolidines are usually prepared by the reaction of norephedrine or ephedrine with borane-THF or borane dimethylsulfide complex.4c Their extreme sensitivity to air and moisture make these reagents difficult to purify by distillation or recrystallization, and therefore, they are commonly prepared in situ for subsequent reactions.9 However, side products present with the unpurified B-H heterocyclic catalysts or reagents cause a detrimental effect on the enantiomeric purity of desired chiral products.10 Furthermore, when B-H oxazaborolidines are left over a period of time can form dimers or oligomers that alter the nature of the chiral catalyst.4d,11 On the contrary, B-alkylated compounds are more stable, easier to purify and handle than the nonsubstituted counterparts, and produce similar enantioselectivities.5e B-substituted 1,3,2-oxazaborolidines are typically prepared by condensation of the amino alcohols with boronic acids,5a boroxines,5d,5e or their boronate esters,4c removing water and boronic acid, or boronic ester residues, by azeotropic distillation in toluene.5d The treatment of chiral amino alcohols with organo-bis(diisopropylamino)borane for the synthesis of B-alkyl and phenyl oxazaborolidines has also been reported.12 However, these methods require expensive and elaborated reagents, and moreover, the complete removal of water is extremely difficult.
Herein, we describe a novel approach for one pot synthesis of pure B-alkyl-1,3,2-oxazaborolidines derived from ephedrine and norephedrine via alkylation of the parent boraheterocyclic compound 1, as indicated in scheme 1.13
Scheme 1.
In our previous work,14 we observed an unprecedented B-alkylation of the oxazaborolidine 1 derived from (1R, 2S)-(−)-norephedrine by the n-butyllithium addition, forming the corresponding cyclic borohydride 2, as illustrated in scheme 2. After an aqueous work-up, the boronic acid derivative 3b was isolated in 91% crude yield, as clear oil, and identified by 11B, 1H, 13C NMR and IR spectral data.15 Intermediate 3b was observed to be stable to acid and base hydrolysis and can be potentially valuable as a suitable source for the heterocyclic catalyst 4b. Contrary to the butylboronic acid condensation procedure to prepare 4b, used by Garcia and coworkers,5d the formation of this compound was successfully completed by heating 3b, obtaining a 75% yield of the distilled product with more than 95% purity by GC/MS, 1H and 13C NMR.16
Scheme 2.
The approach given in scheme 2 was then investigated for the synthesis of other common B-alkyl 1,3,2-oxazaborolidines derived from (1R, 2S)(−)-norephedrine and (1R, 2S)-(−)-ephedrine. Initially, the B-H oxazaborolidines were synthesized by a modification of the established condensation reaction of the corresponding chiral 1,2-amino alcohol with borane-THF,4c,d and characterized by 11B and 13C NMR spectroscopy.4d,17 The boron alkylation with n-butyl-, or methyllithium, of the in situ prepared B-H oxazaborolidine took place readily at −78 °C, forming the lithium borohydride salt 2. Upon treatment with an aqueous ammonium chloride solution, extraction with ether or dichloromethane, and drying the organic phase with sodium sulphate, produced the crude boronic acid intermediate 3 with good purity (> 85% by GC/MS) and excellent yield, as illustrated in Table 1.
Table 1.
Boronic Acid Derivatives Prepared by Alkylation of the B-H Oxazaborolidine 1
| Compound 3 | Bp. (°C/mmHg) | 11B-NMRa (δ, ppm) | Yieldb,c (%) |
|---|---|---|---|
3a
|
95/0.7 | 7.1 | 80 |
3b
|
- | 8.0 | 91 |
3c
|
120/0.5 | 8.1 | 75 |
3d
|
110/0.1 | 8.5 | 97 |
Chemical displacements using BF3-OEt2 as internal standard.
Yield of crude product based on the corresponding amino alcohol.
Pure compounds were not obtained due to partial dehydration during distillation.
In the case of analogues 3a,c and d, the yields of the pure B-alkyl-oxazaborolidines obtained by the previous dehydration method were modest because the boronic acid intermediate 3 co-distilled with the oxazaborolidine. The yields of the desired heterocyclic products were only slightly improved by azeotropic distillation of the water using toluene or xylene and 4Å molecular sieves.5d In addition, other side products were observed by GC/MS.
After attempting to find a better alternative to prepare the B-alkylated oxazaborolidine from the borohydride intermediate 2 by treatment with MeI or TMSCl, the use of anhydrous ammonium chloride provided the expected oxazaborolidines in good yield and with excellent purity as indicated by GC/MS, 11B, 1H and 13C NMR.16 The boiling points and 11B NMR signals of B-methyl and n-butyl substituted oxazaborolidines 4, and the isolated yields of the analytical pure compounds prepared by the aqueous and dry methods, are shown in table 2.
Table 2.
B-Alkyl Oxazaborolidines Prepared by B Alkylation of the Parent Heterocyclic Compound
| Compound 4 | Bp. (°C/mmHg) | 11B-NMRa (δ, ppm) | Yieldb (%) |
|---|---|---|---|
4a
|
42/0.12 | 32 | 65 48c |
4b
|
82/0.1 | 35 | 56 75c |
4c
|
80/2.0 | 34 | 58 45c |
4d
|
84/0.55 | 34 | 70 50c |
Chemical displacements using BF3-OEt2 as internal standard.
Yield based on the corresponding amino alcohol by treatment of 2 with anhydrous ammonium chloride followed by fractional distillation.
By treatment of 2 with aqueous ammonium chloride and calculated from crude product 3.
Typical experimental procedure
To a solution of Borane-THF (43 mmol, 43 mL, 1.0 M) at room temperature was added drop-wise a solution of (1R, 2S)(−)norephedrine (2.5 g, 15.5 mmol) in THF (25 mL). After the clear reaction mixture was stirred for 12 hr at room temperature, the solvents were removed under vacuum (20 mmHg) and the white foamy residue was gradually heated in an oil bath to 130°C and maintained at this temperature for 30 min. A clear crystalline solid compound was obtained, which by 11B, 1H and 13C NMR was similar to the B-H-1,3,2-oxazaborolidine reported by Quallich.17 A solution of n-BuLi (18.6 mmol, 8.0 mL, 2.32 M in hexanes) was added in 15 min to the previous obtained solid dissolved in anhydrous ether (30 mL) and cooled at −78°C. The mixture was stirred overnight at 25°C. The pale rose mixture with a fine suspension was cooled at 0°C and then allowed to react with solid ammonium chloride (4.4g, 82.5 mmol) for 4 h at room temperature. The solid was removed by filtration using a Schlenk filter under nitrogen flow and vacuum (15 mmHg). The filtrated was concentrated using a vacuum pump and heated at 40°C obtaining the crude product (3.9 g, 99% yield). A short path distillation at reduced pressure furnished the pure B-butyl-1,3,2-oxazaborolidine 4b as a clear oil (2.0 g, 56%, 98% purity by GC/MS); Bp 82 °C/0.1 mmHg; IR (ν cm−1) 3219 (NH); 11B NMR (500 MHz), δ (CDCl3, ppm) 35; 1H δ 7.3 (m, 5H), 7.50 (d, J = 6 Hz, 1H), 3.9 (m, 1H), 3.5 (br. s, 1H, NH), 1.5 (m, 4H), 0.9 (m, 5H), 0.6 (d, J = 6 Hz, 3H); 13C δ 139.6, 127.7, 127.2, 126.7, 126.1, 82.1, 53.8, 27.3, 25.4, 20.4, 13.8, 11.3 (br.); MS (m/z): 216.9 (M+.), 202 (100%).
In summary, we have achieved the first efficient and direct approach to B-alkylated oxazaborolidines derived from ephedrine and norephedrine via alkylation of the B-H precursors, opening a new avenue for the preparation of other important B-substituted oxazaborolidines, which are presently under study.
Supplementary Material
Acknowledgments
Financial support by the National Institute of Health through their MBRS (GM 08216) and NIH-AREA (GM 59829) grants is greatly appreciated. The NIH-MARC, DOD-ONR and NSF-AMP undergraduate’s support is also gratefully acknowledged. From the University of Puerto Rico, Río Piedras, we thank Professor John A. Soderquist for his helpful discussions and Mr. José Martínez for obtaining the NMR spectra.
Footnotes
Supporting Information Available. Spectroscopic data from B-alkylated oxazaborolidines. This material is free of charge via Internet at http://pubs.acs.org.
References
- 1.Hirao A, Itsuno S, Nakahama S, Yamazaki Y. J Chem Soc, Chem Commun. 1981:315–317. [Google Scholar]
- 2.(a) Corey EJ, Helal CJ. Angew Chem Int Ed. 1998;37:1986–2012. doi: 10.1002/(SICI)1521-3773(19980817)37:15<1986::AID-ANIE1986>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]; (b) Deloux L, Srebnik M. Chem Rev. 1993;93:763–784. [Google Scholar]; (c) Singh VK. Synthesis. 1992:605–617. [Google Scholar]; (d) Wallbaum S, Martens J. Tetrahedron: Asymm. 1992;3:1475–1504. [Google Scholar]
- 3.(a) Nakagawa M, Kawate T, Kakikawa T, Yamada H, Matsui T, Hino T. Tetrahedron. 1993;49:1739–1748. [Google Scholar]; (b) Fontaine E, Namane C, Meneyrol J, Geslin M, Serva L, Roussey E, Tissandie S, Maftouh M, Roger P. Tetrahedron: Asymm. 2001;12:2185–2189. [Google Scholar]; (c) Puigjaner C, Vidal-Ferran A, Moyano A, Pericas MA, Riera A. J Org Chem. 1999;64:7902–7911. [Google Scholar]
- 4.(a) Seerden J-PG, Boeren MMM, Scheeren HW. Tetrahedron. 1997;53:11843–11852. [Google Scholar]; (b) Corey EJ, Cimprich KA. J Am Chem Soc. 1994;116:3151–3152. [Google Scholar]; (c) Joshi NN, Srebnik M, Brown HC. Tetrahedron Lett. 1989;30:5551–5554. [Google Scholar]; (d) Brown JM, Lloyd-Jones GC. Tetrahedron: Asymm. 1990;1:869–872. [Google Scholar]
- 5.(a) Caze C, El-Moualij N, Hodge P, Lock CJ, Ma J. J Chem Soc, Perkin Trans 1. 1995:345–349. [Google Scholar]; (b) Cho BT, Chun YS. Tetrahedron Asymm. 1992;3:1539–1542. [Google Scholar]; (c) Berenguer R, Garcia J, Vilarrasa J. Tetrahedron: Assymm. 1994;5:165–168. [Google Scholar]; (d) Bach J, Berenguer R, Jordi Garcia J, Loscertales T, Vilarrasa J. J Org Chem. 1996;61:9021–9025. doi: 10.1021/jo9612943. [DOI] [PubMed] [Google Scholar]; (e) Quallich GJ, Blake JF, Woodall TM. Diphenyloxazaborolidines for Enantioselective Reduction of Ketones. In: Abdel-Magid AF, editor. Reductions in Organic Synthesis. Chapter 7. American Chemical Society; Washington, DC: 1996. pp. 112–126. [Google Scholar]; (f) Quallich GJB, James F, Woodall Teresa M. J Amer Chem Soc. 1994;116:8516–8525. [Google Scholar]
- 6.(a) Cho TB, Ryu MH. Bull Korean Chem Soc. 1994;15:191–192. [Google Scholar]; (b) Cho BT, Ryu MH, Chun YS, Dauelsberg C, Wallbaum S, Martens J. Bull Korean Chem Soc. 1994;15:53–57. [Google Scholar]; (c) Dougherty JT, Flisak JR, Hayes J, Lantos I, Liu L, Tucker L. Tetrahedron Asymmetry. 1997;8:497–500. [Google Scholar]
- 7.Brown JM, Lloyd-Jones GC. J Chem Soc, Chem Commun. 1992:710–713. [Google Scholar]
- 8.Cho BT, Chun YS. Bull Korean Chem Soc. 1996;17:1096–1098. [Google Scholar]
- 9.Sakito Y, Yoneyoshi Y, Suzukamo G. Tetrahedron Lett. 1988;29:223–224. [Google Scholar]
- 10.Mathre DJ, Thompson AS, Douglas AW, Hoogsteen K, Carroll JD, Corley EG, Grabowski EJJ. J Org Chem. 1993;58:2880–2888. [Google Scholar]
- 11.(a) Brown JM, Lloyd-Jones GC, Layzell TP. Tetrahedron: Asymm. 1993;4:2151–2154. [Google Scholar]; (b) Nevalainen V. Tetrahedron Asymm. 1994;5:387–394. [Google Scholar]
- 12.Chavant PY, Vaultier M. J Organometallic Chem. 1993;455:37–46. [Google Scholar]
- 13.Ortiz-Marciales M, De Jesús M, González E, Espinosa S, Correa W. 60/445, 743. US Patent Application. 2003 Feb;
- 14.Ortiz-Marciales M, González E, Figueroa R, Martínez J, Muñoz X, Espinosa S, Correa W. Presentation 820, Abstracts of Papers, 223rd National Meeting of the American Chemical Society; Orlando, Fl. Washington, DC: American Chemical Society; 2002. CHED. [Google Scholar]
- 15.(a) NMR in CDCl3 (δ ppm): 11B 9.2; 1H 7.3-6.9 (m, Ph); 4.9 (d, J = 5.2, PhCH-O); 4.4 (s, br, OH); 3.4 (m, CH-N); 3.0 (s, br, NH2); 1.2-1.1 (m, CH2); 0.87-0.79 (m, CH2, CH3); 0.67 (d, J = 5.3, CH3); 13C 140.9 (Cpara), 128-126, 77.4 (PhCH-O), 53.1 (CH-N), 27.2, 26.7, 20.6, 14.3; IR (ν cm−1): 3352 (br, OH, NH2) 1603 (br, NH2). GC/MS (70ev, m/z) 217 (M+.–H2O), 202 (100%). (b) This compound is new, however no analytical sample could be obtained due to its partial dehydration on purification. (c) B-phenyl boronic acid intermediates formed by the addition of water to oxazaborolidines were reported by Rico AR, Tlahuextl M, Flores-Parra A, Contreras R. J Organomet Chem. 1999;581:122–128.
- 16.See supporting information.
- 17.Quallich GJ. 6,037505. US Patent. 2000 May 14;
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.


